Moderna (MEX:MRNA) Receivables Turnover : 2.16 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Moderna Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Moderna's Revenue for the three months ended in Sep. 2024 was MXN36,526 Mil. Moderna's average Accounts Receivable for the three months ended in Sep. 2024 was MXN16,891 Mil. Hence, Moderna's Receivables Turnover for the three months ended in Sep. 2024 was 2.16.

Moderna Receivables Turnover Historical Data

The historical data trend for Moderna's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Receivables Turnover Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

2.90

0.39

7.84

7.99

5.44

Moderna Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Receivables Turnover	Get a 7-Day Free Trial															1.71	2.00	0.32	1.54	2.16

Competitive Comparison of Moderna's Receivables Turnover

For the Biotechnology subindustry, Moderna's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Moderna's Receivables Turnover falls into.

Moderna Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Moderna's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	114644.071	/ (	(27001.96	+	15141.029)	/	2 )
=	114644.071	/	21071.4945
=	5.44

Moderna's Receivables Turnover for the quarter that ended in Sep. 2024 is calculated as

	Receivables Turnover (Q: Sep. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Sep. 2024 )	/ (	(Accounts Receivable (Q: Jun. 2024 )	+	Accounts Receivable (Q: Sep. 2024 ))	/	count )
=	36525.507	/ (	(2986.177	+	30795.629)	/	2 )
=	36525.507	/	16890.903
=	2.16

Moderna (MEX:MRNA) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Moderna Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Moderna's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (MEX:MRNA) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru 1MRNA:Italy 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.